| Date Filed | Type | Description |
| 10/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/25/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in TAYSHA GENE THERAPIES, INC. |
| 08/25/2023 |
4
| Alam Kamran (CFO) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Sold 33,000 shares
@ $2.33, valued at
$76.9k
|
|
| 08/25/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/25/2023 |
SC 13G
| TCG Crossover GP I, LLC reports a 5.9% stake in Taysha Gene Therapies, Inc. |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/21/2023 |
SC 13D/A
| Manning Paul B reports a 12.6% stake in Taysha Gene Therapies, Inc. |
| 08/18/2023 |
SC 13D/A
| Astellas Pharma Inc. reports a 3.9% stake in TAYSHA GENE THERAPIES, INC. |
| 08/16/2023 |
4
| Manning Paul B (10% Owner) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Bought 16,466,667 shares
@ $0.9, valued at
$14.8M
|
|
| 08/16/2023 |
4
| Stalfort John A III (Director) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Bought 388,889 shares
@ $0.9, valued at
$350k
Bought 388,889 shares
@ $0.9, valued at
$350k
Gifted 50,000 shares
@ $0 |
|
| 08/16/2023 |
4
| Nolan Sean P. (CEO) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Bought 444,444 shares
@ $0.9, valued at
$400k
|
|
| 08/16/2023 |
4
| Donenberg Phillip B. (Director) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Bought 111,111 shares
@ $0.9, valued at
$100k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
4
| Session R.A. II (10% Owner) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Sold 80,528 shares
@ $0.7082, valued at
$57k
Sold 5,344 shares
@ $0.7, valued at
$3.7k
|
|
| 06/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
4
| Nagendran Sukumar (President and Head of R&D) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Bought 5,000 shares
@ $0.68, valued at
$3.4k
|
|
| 05/15/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/08/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/08/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/27/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
|